CLEVELAND, July 26, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's only FDA-cleared MRI-guided radiation therapy system, announced today that the company's MRIdian® System is the focus of 55 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2018 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year's meeting will be held July 29-August 2 in Nashville.
Presentations focused on MRIdian MRI-guided radiation therapy at this year's meeting include abstracts from global MRIdian institutions including Washington University, Henry Ford Health System, University of California Los Angeles (UCLA), University of Wisconsin, University of Miami, National Cancer Center Hospital in Tokyo, and Seoul National University Hospital.
Noteworthy abstracts featured in AAPM's Scientific Program include presentations from National Cancer Center Hospital in Tokyo and Washington University, both highlighting the benefits and quality of MRIdian's daily on-table adaptive and re-optimization capabilities in terms of both disease coverage and sparing of surrounding organs at risk. Presentations from Henry Ford Health System and National Cancer Center Hospital in Tokyo each showcase MRIdian's accurate treatment of tumors that move with respiration with excellent duty cycles (ratio of beam-on time to total treatment time).
Other presentations given by University of Miami and UCLA will highlight MRIdian's potential radiomics applications toward the assessment of disease origin and/or prediction of clinical response to treatment, including the potential ability to predict necrosis through longitudinal diffusion MRI.
AAPM attendees can also learn more about MRIdian and MRI-Guided Real-time, On-table, Adaptive Radiotherapy (ROAR) in ViewRay's booth #413 where MRIdian clinical users from UCLA, Washington University, University of Wisconsin, University of Miami, VUmc Amsterdam, and Henry Ford Health System will present throughout the meeting.
Also in the ViewRay booth will be demonstrations of the company's latest technological advances designed to improve tumor and soft tissue visualization as part of MRIdian's SmartVISIONTM technology. These technologies, which are currently pending 510(k) clearance1, include new T1w and T2w MR pulse sequences and Diffusion Weighted functional imaging (DWI) designed to enhance the contrast between cancerous and healthy tissues and potentially assess and predict tumor response to radiation therapy. Other potential enhancements from these technologies include a 2X increase in MR imaging speed as compared to previous generation systems, stepping up from 4 frames to 8 frames per second, along with 2X higher image resolution and a 2X improvement in MR signal-to-noise ratio (SNR) for brighter, more detailed anatomical imaging.
For a full schedule of in-booth presentations, and AAPM Scientific Program presentations on MRIdian and MRIdian Linac, please visit www.viewray.com/aapm-2018.
- FDA 510(k) pending items are not available for sale or distribution in the United States.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may potentially arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to, the advancement of science, specifically that further analysis and investigations substantiate or confirm data and findings from abstracts, and the ability of MRI-guided radiation therapy programs to enable improved tumor targeting precision, organ at risk sparing, predictive radiomics, disease coverage, duty cycles and workflow, and that such programs may potentially reduce side effects. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
View original content:http://www.prnewswire.com/news-releases/leading-medical-physics-meeting-to-feature-more-than-50-presentations-on-viewrays-mridian-mri-guided-radiotherapy-300687432.html
SOURCE ViewRay, Inc.
Michael Saracen, Vice President, Marketing, ViewRay, Inc., Phone: +1 408-242-2994, Email: firstname.lastname@example.org